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Despite the huge effort to contain the infection, the novel SARS-CoV-2 coronavirus has rapidly
become pandemics, mainly due to its extremely high human-to-human transmission capability, and
a surprisingly high viral charge of symptom-less people. While the seek of a vaccine is still ongoing,
promising results have been obtained with antiviral compounds. In particular, lactoferrin is found to
have beneficial effects both in preventing and soothing the infection. Here, we explore the possible
molecular mechanisms with which lactoferrin interferes with SARS-CoV-2 cell invasion, preventing
attachment and/or entry of the virus. To this aim, we search for possible interactions lactoferrin
may have with virus structural proteins and host receptors. Representing the molecular iso-electron
surface of proteins in terms of 2D-Zernike descriptors, we (i) identified putative regions on the
lactoferrin surface able to bind sialic acid receptors on the host cell membrane, sheltering the cell
from the virus attachment; (ii) showed that no significant shape complementarity is present between
lactoferrin and the ACE2 receptor, while (iii) two high complementarity regions are found on the
N- and C-terminal domains of the SARS-CoV-2 spike protein, hinting at a possible competition
between lactoferrin and ACE2 for the binding to the spike protein.
I. INTRODUCTION
Lactoferrin (Lf) is a versatile glycoprotein, which plays
a key role in many biological functions [1]. In this work,
we focus on the Lf as a crucial player in natural immunity,
since it has been proposed to play a strong antiviral activ-
ity against a wide range of RNA and DNA viruses [2–6].
Lf is composed of a single chain of about 700 residues
folded into two symmetrical lobes. Each lobe possesses a
metal-binding site, able to bind iron but also other ions
like Cu2+, Zn2+ and Mn3+ [7, 8].
This protein is present in saliva, tears, seminal fluid,
white blood cells, and milk of mammals [9]. From its
discovery in 1939 [10, 11] lactoferrin has been identified
as the most important iron-binding protein in milk. Be-
sides, in recent years, lactoferrin has been found involved
in a multitude of biological processes. In fact, despite
the name, the iron cargo capacity of Lf is not the promi-
nent activity exerted by this molecule. Instead, it per-
forms antioxidant, anti-inflammatory, and anticancer ac-
tivities [8, 12], together with a broad antimicrobial action
against bacteria and fungi. The latter activity, in partic-
ular, is due to Lf’s ability to reversibly bind two atoms
of iron with high affinity in the presence of bicarbon-
ate. The iron-free form of Lf, apo-lactoferrin (apoLf),
deprives bacteria of iron, thus inhibiting their metabolic
activities in vivo.
Besides all the aforementioned activities, Lf has been
demonstrated to prevent infection of a wide range of di-
verse viral species [13].
Many viruses make use of glycans, such as sialic acid
(SIA) or glycosaminoglycan, like heparan sulfate (HF) as
attachment factors. See, for example, [14] for details on
glycans. When the contact between the virus particle and
these receptors is established, they roll toward their spe-
cific viral receptor and subsequently enter the host cell,
for instance by fusing with the host cell membrane [15].
While the interaction between Lf and HF has been
observed [16], studies on its interaction with sialic acid
derivatives are still missing. On the other hand, Lf has
been reported to interact with virus structural proteins,
S, M, and E [17].
In general, depending on the specifics of the virus,
lactoferrin prevents infection of the target cell by either
(i) interfering with the attachment factor or (ii) by bind-
ing to host cell molecules that the virus uses as a receptor
or co-receptor (competition) or (iii) by direct binding to
virus particles, as described for herpesvirus [18], polio-
and rotavirus [19, 20], and possibly human immunod-
eficiency virus [21]. See, for example, [22] for a more
detailed discussion.
While we are writing this article, a novel virus, first
observed in the autumn of 2019, has rapidly become
pandemic. This virus, called SARS-CoV-2, belongs to
the coronavirus family and causes severe acute respira-
tory syndrome [23, 24], somewhat similar to those caused
by two other coronaviruses, SARS-CoV and MERS-
CoV, which crossed species in 2002-2004 [25, 26] and
2012 [27]. In fact, SARS-CoV-2, similarly to SARS-
CoV and MERS-CoV, attacks the lower respiratory sys-
tem, thus provoking viral pneumonia. However, this in-
fection can also lead to effects on the gastrointestinal
system, heart, kidney, liver, and central nervous system
[24, 28, 29].
As for SARS-CoV [30–32], recent in vivo experiments
confirmed that also SARS-CoV-2 cell entry is medi-
ated by high-affinity interactions between the receptor-
binding domain (RBD) of the virus S glycoprotein
and the human-host Angiotensin-converting enzyme 2
(ACE2) receptor [33]. The spike protein is located on the
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2virus envelope and promotes the host attachment and fu-
sion between the viral and cellular membrane. [34, 35].
Structural studies determined the structures of such pro-
tein both in free form and bound to ACE2 [36]. Further
studies investigate the possible interaction of SARS-CoV-
2 to sialic acids [37–40] or heparan surfate receptors [39],
both considered involved in SARS-CoV-2 as well as in
other coronavirus infections [14, 16, 41–43].
While the use of Lf as an antiviral against previous
coronaviruses infections has been poorly investigated, ex-
cept for [16], where evidence of an effect in the attach-
ment process is shown, new studies are proving the an-
tiviral effect of Lactoferrin against the novel SARS-CoV-
2 infection. In particular, administration of a liposomal
formulation of Lf to a significant sample of Covid-19 pos-
itive patients, has been shown to provide an immediate
beneficial effect [44].
Here, we computationally investigate the possible
molecular mechanisms behind the observed antiviral ac-
tion of lactoferrin. In particular, we make use of a re-
cently developed computational protocol based on the
2D Zernike Polynomials, able to rapidly characterize the
shape conformation of given protein regions [37]. In this
framework using a simple pairwise distance, it is possible
to evaluate the similarity between 2 protein pockets or
the shape complementarity between the binding regions
of 2 interacting proteins.
In order to assess whether lactoferrin could influence
the attachment factors, we investigated the ability of Lt
to bind to sialic acid (SIA) or heparan sulfate (HS) re-
ceptors [14], both considered involved in SARS-CoV-2
infection [37–40] as well as to other coronavirus infec-
tions [16, 41–43].
We moreover checked for a possible direct interaction
between LF and ACE2 receptor, which could inhibit the
interplay between spike and ACE2 binding necessary to
the virus infection.
Finally, we investigate the possible interaction between
Lf and the 3 proteins present on the SARS-CoV-2 mem-
brane, i.e. the spike (S), membrane (M), and envelope
(E) proteins.
II. RESULTS
The entry of the virus inside the host cells requires the
occurrence of a sequence of molecular interactions. Sialo-
side (SIA) and/or heparan sulfate (HF) chains mediate
the attachment of the virion to the cell surface. Once
in the proximity of the cellular receptor (ACE2), SARS-
CoV-2 spike protein binds to the receptor and initiates
the internalization process. Figure 1a shows a sketch of
the mechanism. The observed antiviral action of Lf may
consist of interference in one or more of those steps. We
thus investigate in the next three sections the possibility
of direct binding between lactoferrin and SIA, ACE2, and
SARS-CoV-2 Spike protein, respectively (see Figure 1b).
A. Interaction with SIA
Possible binding regions for sialic acid, the termi-
nal molecule of the SIA receptors on human lactoferrin
are investigated on the basis of the procedure described
in [37], i.e. we select the portion of the molecular surface
of the MERS-CoV spike protein in interaction with sialic
acid, experimentally solved in [45] (Figure 2a), and we
search for similar patches on the Lf molecular surface.
Within the same strategy, we search for similar patches
on the surface of human lactoferrin.
In the 2D Zernike framework, the geometrical shape of
a protein surface patch is compactly summarized in a set
of ordered numerical descriptors, whose number - 121 in
our case - modulate the detail of the description. Deal-
ing with ordered numerical descriptors, the comparison
between different protein patch can be performed with a
Euclidean distance.
Figure 2b and c show the four most geometrically sim-
ilar patches identified in the Apo and Holo form of Lf.
An a posteriori check of the electrostatic potential on the
patches, allows us to select only some of the possible solu-
tions identified based on the shape comparison analysis,
i.e. the ones having also a similar electrostatic surface
with the SIA binding site on the MERS-CoV spike.
The region on Lf surface identified as the most similar
to the MERS region interacting with sialic acid, both in
shape and in electrostatics, is the one centered on VAL
346.
B. Interaction with ACE2
To check whether the action of lactoferrin can be as-
cribed to a competition with the virion spike proteins
in binding directly the ACE2 receptor (Figure 1), we
performed a blind search of the molecular surfaces of
both ACE2 and human Lf to identify possible binding
regions having a meaningful shape complementarity. Un-
der this hypothesis, if the interaction between the Lf and
the ACE2 receptor occurs, Lf could hinder the molec-
ular binding between the spike protein of SARS-CoV-2
and the corresponding ACE2 receptor. Figure 3 shows
the molecular surface of the ACE2 receptor colored ac-
cording to its propensity to bind regions of the Lf protein.
The redder the region, the greater the shape complemen-
tarity between that region and another one found on the
surface of the putative molecular partner, i.e. holo lacto-
ferrin. As one can see from Figure 3, a complementary
region is indeed present, however, it is located far from
the binding site of the spike (grey in the figure) and in a
part of ACE2 that looks toward the membrane. To bet-
ter visualize the result, we have represented two points of
view of the binding between spike and ACE2, one rotated
180o with respect to the other. On the other hand, we
can see that the ACE2 region interacting with the SARS-
CoV-2 spike protein has no low shape complementarity
with Lf regions.
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FIG. 1: SARS-CoV-2 attachment and entry to host cell in physiological condition and possible actions of
lactoferrin. a) Sketch of SARS-CoV-2 initial interactions with the host cell. Sialoside (SIA) and heparan sulfate (HS) glycan
chains present on glycoproteins (PG) of the cell membrane are thought to facilitate the attachment of the virion to the cell
surface. This favors the establishment of an interaction between the virus spike protein and the ACE2 receptor, which starts
the internalization of the virus in the host cell. b) Human lactoferrin has been found to play an antiviral action against SARS-
CoV-2 infection although it is not clear whether this action consists in (1) competition for the binding with glycan chains,
and/or (2) competition for binding ACE2 receptor and/or (3) direct interaction with one of the proteins in the virion envelope,
i.e. with S, M or E proteins.
C. Interaction with virion membrane proteins
A third possible mechanism at the basis of the observed
antiviral activity of Lf could be ascribed to a direct inter-
action with the membrane proteins present on the virion
envelope. In particular, SARS-CoV-2 presents three dif-
ferent kinds of proteins on its membrane, i.e. S, M, and
E proteins [46, 47]. While the 3D structure of the S pro-
tein has been determined - even if some loop regions in
the S1 sub-unit are not solved - unfortunately, no struc-
tures are available for the E and M proteins. Thus, the
molecular surfaces of Lf were compared with those of the
three proteins in order to check whether an interaction
with lactoferrin is possible. For this analysis, we adopted
the same computational procedure used in the previous
paragraph.
For both S, M, and E proteins, we sample their whole
molecular surface and compared all the possible patches
with those of Lf. In this way, all molecular surfaces, both
membrane proteins, and Lf ones are colored according to
the corresponding binding propensity.
E and M presented a possible region of interactions
located in the intra-membrane region (data not shown).
The most robust and relevant result of this analysis re-
gards the compatibility between the spike and lactoferrin.
According to our findings, Lf presents two regions of high
complementarity with one portion of the C-terminal do-
main of the spike S1 subunit and another located in the
N-terminal part.
To test the reliability of the found signals, we per-
formed a molecular dynamics simulation of the spike
trimer (see Methods for details) and sampled 5 config-
urations for each of the three chains at equilibrium (see
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FIG. 2: Putative sialic-binding regions on human lactoferrin. a) Cartoon representation of the sialic-acid binding
region of MERS-CoV (PDB id: 6Q04) and its representation in the Zernike disk (left) and local Coulombic surface (right).
b) Four most complementar regions on holo human lactoferrin (PDB id: 1LFG) obtained comparing the lactoferrin molecular
surface with the sialic acid binding region of MERS-CoV. c) Same as in b) but for the apo human lactoferrin (PDB id: 1CB6).
Molecular surfaces are colored according to the Coulombic potential.
Figure 4a).
In particular, for each chain, we performed a Principal
Component Analysis (PCA) on the frames of the dynam-
ics and thus projected them on the plane identified by the
two principal components. Upon clustering these points
we obtain 5 subgroups. For each subgroup, we extract the
centroidal configuration. Since distant points in the PCA
plane correspond to the different 3D structure, picking
one point from each identified cluster assured that the
selected configurations have high structural differences
between them in the explored configuration space (see
Figure 4b).
Remarkably, repeating the blind search for comple-
mentarity regions on the 15 surfaces of the extracted
spike monomers, we found conservation of the signal over
the conformational noise. Figure 4c) shows the identified
regions and their conservation in the different sampled
frames.
Among the found regions, the one involving the spike
C-terminal domain is the one with higher shape comple-
mentarity. In particular, according to our method, hu-
man lactoferrin could interact with the spike protein with
the surface region centered in residue ALA 539. Alter-
natively, the spike protein may interact with the Lf pro-
tein using a molecular patch centered in the residue PHE
490. It must be pointed out that the complementarity
achieved by these patches is comparable with those of
experimentally solved complexes. Indeed, analyzing the
shape complementarity of over 4600 x-ray protein-protein
complexes (see Methods for details), we have the distri-
bution shown in Figure 4d, where the lower the distance
the higher the complementarity of the binding region.
Red dotted line shows the complementarity found be-
tween the spike and Lt. As it is evident the proposed
patch is characterized by values of shape complementar-
ity typical of experimental complexes.
Finally, to further support this result with an inde-
pendent and external methodology to our approach, we
performed a completely blind molecular docking analy-
sis between the spike protein and the Lf protein. To
this end, Zdock server was used as a state of the art of
molecular docking software [48]. As per default settings,
only the first 10 docking poses have been selected and the
predicted contacts analyzed. In particular, five out of ten
poses show bindings involving the spike region involve the
region we found with our protocol when the residues are
defined in contact if their C-alpha atoms have a distance
less than 8 A˚.
5FIG. 3: Analysis of the binding between lactoferrin
and the ACE2 receptor. Molecular representation of the
experimentally solved complex of the ACE2 receptor with
SARS-CoV-2 spike protein. The ACE2 molecular surface is
colored according to its binding propensity to bind lactofer-
rin regions. Dark red indicates high binding propensity while
white means no interaction.
III. DISCUSSION
In the last decade, the Zernike formalism has been
widely applied for the characterization of molecular sur-
faces [49–53].
Very recently, we developed a new representation,
based on the 2D Zernike polynomials, which allows an
extremely efficient, fast, and completely unsupervised
description of the local geometrical shape, allowing for
easy comparison between different regions of molecules.
Through this compact description, it is possible both to
analyze the similarity between 2 different regions - sug-
gesting, for example, a similar ligand for binding regions
- and to study the complementarity between interacting
surfaces [37].
Here, we used our novel method to shed some light
on the molecular mechanisms ruling the observed antivi-
ral action human lactoferrin exerts against SARS-CoV-2
infection [44].
In particular, we focused on the early stages of the
infection, i.e. the attachment and entry of the virus to the
host cell, when lactoferrin can interfere with the virus-
host interaction without the need to be internalized in
the cell. We thus tried to establish whether lactoferrin
could compete with the virus in binding to sialic acid, the
sticky end of sialoside chains, which has been suggested
to mediate the attachment of SARS-CoV-2 to the host
cell. Interestingly, comparing the binding region of sialic
acid in the MERS-CoV coronavirus with patches on the
lactoferrin surface, we found possible spots on both apo
and holo forms of Lf, which could compete in forming
low affinity but high avidity interactions.
We then proceeded to test the hypothesis of an inter-
action between lactoferrin and the primary SARS-CoV-
2 protein receptor, ACE2. A blind search for comple-
mentarity regions highlighted a hot-spot in a region that
in physiological conditions is oriented toward the mem-
brane, while no significative complementarity is present
in the ACE2 region involved in the interaction with the
virus spike protein. At last, we analyzed the three mem-
brane proteins on the virus envelope, i.e. the E, M, and S
ones. Similarly to ACE-2, both E and M presented possi-
ble interacting regions in portions of the surface, that are
buried in the virion membrane under normal conditions
(data not shown). On the other hand, the spike protein
showed two main hot spots, one in the N-terminal do-
main of the S1 subunit and another in the C-terminal
one. Those two regions are robust to molecular noise, as
the signal endures using different configurations sampled
from a molecular dynamics simulation and each of the
three chains of the trimer. Notably, the most comple-
mentary region is the one in the C-terminal region, the
one involved in the spike-ACE2 interaction. Thus our
finding suggests a possible competition between ACE2
and lactoferrin for the binding of the SARS-CoV-2 spike,
which may explain the observed antiviral action.
IV. MATERIALS AND METHODS
A. Datasets
The protein, whose structures are analyzed in this pa-
per are:
• Human lactoferrin, in the apo (PDB id: 1CB6) and
holo (PDB id: 1LFG) forms.
• ACE2, in its apo state (PDB id: 1R42).
• SARS-CoV-2 S protein, modeled using I-
Tasser [54].
• SARS-CoV-2 M protein, modeled using I-
Tasser [54].
• SARS-CoV-2 E protein, modeled using I-
Tasser [54].
To set a reference for the measured complementari-
ties, a dataset of protein-protein complexes experimen-
tally solved in x-ray crystallography is taken from [55].
We only selected pair interactions regarding chains with
more than 50 residues. The Protein-Protein dataset is
therefore composed of 4605 complexes. For each com-
plex, the binding region is identified as the portions of
the two protein molecular surfaces distant less than 3 A˚.
B. Computation of molecular surfaces
For each protein of the dataset (x-ray structure in PDB
format [56]), we use DMS [57] to compute the solvent-
accessible surface, using a density of 5 points per A˚2 and
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FIG. 4: Possible interaction between SARS-CoV-2 spike protein and human lactoferrin. a) Root mean square
displacement as a function of time of the SARS-CoV-2 spike trimer as provided by the molecular dynamics simulation.b)
Clustering analysis of the trimer’s A chain in the plane of the two principal components of a PCA analysis over the MD
configurations. Five regions of major variability of the chain are identified. c) Binding propensity computed from the Zernike
descriptors between the 15 most variable conformations of the chains of the SARS-CoV-2 Spike protein and human lactoferrin.
Each residue of the proteins is colored from white to red according to its increasing shape complementarity with the partner. d)
Comparison between the complementarity score (red dashed line) of the best binding site (Zernike disks) and the distribution
of complementarity scores belonging to 4600 binding regions of experimental complexes.
a water probe radius of 1.4 A˚. The unit normals vector,
for each point of the surface, was calculated using the
flag −n.
C. Patch definition and complementarity
evaluation
A molecular surface is represented by a set of points in
the three-dimensional space. We define a surface patch,
as the group of points that fall within a sphere of radius
Rs = 6A˚, centered on one point of the surface. Once the
patch is selected,
• we fit a plane that passes through the points and
reorient the patch in such a way to have the z-axis
perpendicular to the plane and going through the
center of the plane.
• we define the angle θ as the largest angle between
the perpendicular axis and a secant connecting a
given point C on the z-axis to any point of the
patch. C is then set in order that θ = 45◦. r is the
distance between C and a surface point.
• build a square grid and associate each pixel with
the mean r of the points inside it. This 2D func-
tion can be expanded on the basis of the Zernike
polynomials (see next section).
Once a patch is represented in term of its Zernike de-
scriptors, the similarity between that patch and another
one can be simply measured as the Euclidean distance
between the invariant vectors. The relative orientation
of the patches before the projection in the unitary cir-
cle must be considered. In fact, if we search for similar
regions we must compare patches that have the same ori-
entation once projected in the 2D plane, i.e. the solvent-
exposed part of the surface must be oriented in the same
direction for both patches, for example as the positive
z-axis. If instead, we want to assess the complementarity
between two patches, we must orient the patches con-
trariwise, i.e. one patch with the solvent-exposed part
toward the positive z-axis (‘up’) and the other toward
the negative z-axis (‘down’).
7D. 2D Zernike polynomials and invariants
Each function of two variables, f(r, φ) (polar coordi-
nates) defined inside the region r < 1 (unitary circle),
can be decomposed in the Zernike basis as
f(r, φ) =
∞∑
n=0
m=n∑
m=0
cnmZnm (1)
with
cnm =
(n+ 1)
pi
〈Znm|f〉 =
=
(n+ 1)
pi
∫ 1
0
drr
∫ 2pi
0
dφZ∗nm(r, φ)f(r, φ). (2)
being the expansion coefficients, while the complex
functions, Znm(r, φ) are the Zernike polynomials. Each
polynomial is composed by a radial and an angular part,
Znm = Rnm(r)e
imφ. (3)
where the radial part for any n and m, is given by
Rnm(r) =
n−m
2∑
k=0
(−1)k(n− k)!
k!
(
n+k
2 − k
)
!
(
n−k
2 − k
)
!
rn−2k (4)
Since for each couple of polynomials, the following re-
lation holds
〈Znm|Zn′m′〉 = pi
(n+ 1)
δnn′δmm′ (5)
the complete set of polynomials forms a basis and
knowing the set of complex coefficients, {cnm} allows
for a univocal reconstruction of the original image (with
a resolution that depends on the order of expansion,
N = max(n)). Since the modulus of each coefficient
(znm = |cnm|) does not depend on the phase, i.e. it is
invariant for rotations around the origin of the unitary
circle, the shape similarity between two patches can be
assessed by comparing the Zernike invariants of their as-
sociated 2D projections. In particular, we measured the
similarity between patch i and j as the Euclidean dis-
tance between the invariant vectors, i.e.
dij =
√√√√M=121∑
k=1
(zki − zkj )2 (6)
E. Molecular dynamics simulations
The starting structure of the SARS-CoV-2 spike
trimeric complex was taken from the model structure pro-
posed by the I-Tasser server [54]. All steps of the simula-
tion were performed using Gromacs 2019.3 [58]. Topolo-
gies of the system were built using the CHARMM-27
force field [59]. The protein was placed in a dodecahedric
simulative box, with periodic boundary conditions, filled
with 131793 TIP3P water molecules [60]. We checked
that each atom of the trimer was at least at a distance of
1.1 nm from the box borders. The addition of 3 sodium
counterions rendered the systems electroneutral. The fi-
nal system, consisting of 448572 atoms, was first mini-
mized with 2064 steps of steepest descent. Relaxation
of water molecules and thermalization of the system in
NVT and NPT environments were run each for 0.1 ns
at 2 fs time-step. The temperature was kept constant at
300 K with v-rescale algorithm[61]; the final pressure was
fixed at 1 bar with the Parrinello-Rahman algorithm[62]
which guarantees a water density of 1004 kg/m3, close to
the experimental value. LINCS algorithm[63] was used
to constraint h-bonds.
Finally, the systems were simulated with a 2 fs time-
step for 140 ns in periodic boundary conditions, us-
ing a cut-off of 12 A˚ for the evaluation of short-range
non-bonded interactions and the Particle Mesh Ewald
method [64] for the long-range electrostatic interactions.
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